Production (Stage)
Ligand Pharmaceuticals Incorporated
LGND
$105.99
$1.811.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.33M | 42.81M | 51.81M | 41.53M | 30.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.33M | 42.81M | 51.81M | 41.53M | 30.98M |
| Cost of Revenue | 54.93M | 7.26M | 8.12M | 8.26M | 8.85M |
| Gross Profit | -9.60M | 35.55M | 43.69M | 33.27M | 22.13M |
| SG&A Expenses | 18.80M | 25.61M | 24.48M | 17.62M | 10.95M |
| Depreciation & Amortization | 8.26M | 8.26M | 8.26M | 8.26M | 8.19M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.99M | 41.13M | 40.86M | 34.14M | 27.99M |
| Operating Income | -36.66M | 1.69M | 10.96M | 7.39M | 2.99M |
| Income Before Tax | -50.18M | -39.20M | -6.34M | -65.39M | 113.45M |
| Income Tax Expenses | -7.73M | -8.11M | 833.00K | -13.48M | 27.31M |
| Earnings from Continuing Operations | -42.45M | -31.09M | -7.17M | -51.91M | 86.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.45M | -31.09M | -7.17M | -51.91M | 86.14M |
| EBIT | -36.66M | 1.69M | 10.96M | 7.39M | 2.99M |
| EBITDA | -28.35M | 10.31M | 19.95M | 16.24M | 11.75M |
| EPS Basic | -2.21 | -1.64 | -0.39 | -2.88 | 4.86 |
| Normalized Basic EPS | -1.23 | 0.48 | -0.30 | -0.85 | 0.09 |
| EPS Diluted | -2.21 | -1.64 | -0.39 | -2.88 | 4.75 |
| Normalized Diluted EPS | -1.23 | 0.48 | -0.30 | -0.85 | 0.09 |
| Average Basic Shares Outstanding | 19.19M | 18.97M | 18.42M | 18.03M | 17.73M |
| Average Diluted Shares Outstanding | 19.19M | 18.97M | 18.42M | 18.03M | 18.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |